A Phase2, 24 month, Multi-Center, randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study od ACC-001 and QS-21 Adjuvant in Subjects with Mild to moderate Alzeheimer's Disease, Janssen Alzheimer Immunotheraphy